VPS35抗体;VPS35 Antibody—艾普蒂

+ +

•  

   

     Gel: 6%SDS-PAGE, Lysate: 40 μg, Lane 1-7: Hela, HEPG2, Raji, NIH/3T3 and A549 cell lysates, Human cerebella tissue and Mouse brain tissue lysates, Primary antibody: P12900(VPS35 Antibody) at dilution 1/250, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 1 minute    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human colorectal cancer tissue using P12900(VPS35 Antibody) at dilution 1/25. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human thyroid cancer tissue using P12900(VPS35 Antibody) at dilution 1/25. (Original magnification: ×200)    

  
  

VPS35 (Vacuolar Protein Sorting 35 Homolog) is a critical component of the retromer complex, a conserved protein assembly responsible for orchestrating endosome-to-Golgi retrograde transport of cargo proteins. This process is essential for maintaining cellular homeostasis, enabling the recycling of receptors, transporters, and enzymes, thereby regulating diverse physiological functions such as lysosomal degradation, autophagy, and signaling pathways. Dysregulation of VPS35 has been implicated in neurodegenerative diseases, particularly Parkinson’s disease, where specific mutations (e.g., D620N) disrupt retromer function, leading to pathological protein aggregation and neuronal death.

VPS35 antibodies are vital tools for studying the expression, localization, and function of VPS35 in both physiological and disease contexts. These antibodies are widely used in techniques like Western blotting, immunohistochemistry, and immunofluorescence to assess protein levels in tissues or cultured cells. High-quality VPS35 antibodies are rigorously validated for specificity, often using knockout cell lines or tissues to confirm minimal cross-reactivity. Researchers also employ them to investigate interactions within the retromer complex (e.g., with VPS26 and VPS29) or to explore disease mechanisms in models of neurodegeneration, cancer, or metabolic disorders. The development of phospho-specific or mutation-targeting antibodies further aids in dissecting post-translational modifications or pathogenic variants. As therapeutic strategies targeting retromer dysfunction emerge, VPS35 antibodies remain indispensable for preclinical research and biomarker discovery.